Piper Jaffray has issue a report on the positive clinical trial results from Abiomed's ABMD PROTECT II study.
According to the report, "While the trial did not achieve its primary endpoint, there were multiple aspects of it that were encouraging. In particular, in the cohort of patients that did not undergo atherectomy (88% of the study group), patients supported on Impella reported a statistically significant reduction in major adverse events at both 30 and 90 days compared to the control arm's intra aortic balloon pump (IABP). We believe the data will drive adoption of Impella in patients undergoing high risk PCI cases."
ABMD has an Overweight Rating and a $15 Price Target.
ABMD closed yesterday at $14.65 a share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in